II. Medications
III. Mechanism
- Decreased cerebral Cholinergic Activity in Alzheimer Disease, Lewy Body Dementia, Vascular Dementia
-
Cholinergic inhibitors reversibly bind Cholinesterase at Synapse between CNS Neurons
- Results in decreased Acetylcholine degradation, and hence increased Cholinergic Activity
IV. Efficacy
- Minimal clinical benefit, despite Statistically Significant improvement in cognitive function in trials
- Improve neuropsychiatric scores 7 points
- Seven point improvement equals ~1 year of decline
- Benefits may persist for 1-2 years
- Rogers (1998) Arch Intern Med 158:1021-31 [PubMed]
- Meta-analysis shows marginal benefit to risk ratio
- Where NNT is Number Needed to Treat
- NNT for global improvement: 10
- NNT for cognitive improvement: 12
- NNT for significant side effects to stop med: 16
- Lanctot (2003) CMAJ 169:557-64 [PubMed]
V. Adverse Effects
VI. References
Images: Related links to external sites (from Bing)
Related Studies
Concepts | Pharmacologic Substance (T121) |
SnomedCT | 323363000 |
English | Central cholinesterase inhib, Central acetylcholinesterase inhibitor, Central acetylcholinesterase inhibitor (product), Central acetylcholinesterase inhibitor (substance) |
Spanish | inhibidor central de la acetilcolinesterasa (producto), inhibidor central de la acetilcolinesterasa (sustancia), inhibidor central de la acetilcolinesterasa |